Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 21 current clinical trials in our China register. 15 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Atezolizumab, Bevacizumab and Entecavir. The most-studied condition is Acute-On-Chronic Liver Failure.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection
NCT06966908 · ClinicalTrials.gov ↗ · Chronic Hepatitis B
|
Observational | Recruiting | 2025-01 | China |
|
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908 · ClinicalTrials.gov ↗ · Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
|
Not applicable | Recruiting | 2022-08 | China |
|
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
NCT05182463 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic
Drug: Peginterferon alfa-2b |
Phase 4 | Recruiting | 2022-01 | China |
|
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
NCT06562803 · ClinicalTrials.gov ↗ · Acute-On-Chronic Liver Failure, Sepsis
|
Not applicable | Recruiting | 2024-09 | China |
|
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
NCT04231565 · ClinicalTrials.gov ↗ · Hepatitis B Virus
|
Not applicable | Recruiting | 2020-06 | China |
|
Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
NCT04597164 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic, Acute-On-Chronic Liver Failure
|
Observational | Recruiting | 2020-12 | China |
|
Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
NCT06763848 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorders
Drug: Methylprednisolone |
Not applicable | Recruiting | 2025-04 | China |
|
Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
NCT02883647 · ClinicalTrials.gov ↗ · Chronic Hepatitis b
Drug: Entecavir |
Observational | Recruiting | 2014-01 | China |
|
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
NCT07353216 · ClinicalTrials.gov ↗ · Multiple Sclerosis
Drug: Ofatumumab |
Observational | Recruiting | 2023-12 | China |
|
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908 · ClinicalTrials.gov ↗ · Fragility Fracture
|
Not applicable | Recruiting | 2024-01 | China |
|
Cohort Study on Neuroimmune Diseases in the Reproductive Age
NCT07653984 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis
|
Observational | Recruiting | 2024-04 | China |
|
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT05984511 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
Drugs: Atezolizumab, Bevacizumab |
Not applicable | Recruiting | 2023-08 | China |
|
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
NCT03920618 · ClinicalTrials.gov ↗ · Hepatitis B, Acute-On-Chronic Liver Failure
|
Not applicable | Recruiting | 2019-02 | China |
|
Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure
NCT04310787 · ClinicalTrials.gov ↗ · Hepatitis B, Acute-On-Chronic Liver Failure
|
Observational | Recruiting | 2020-05 | China |
|
Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma
NCT05991856 · ClinicalTrials.gov ↗ · Aldosterone-producing Adenoma, Radiofrequency Ablation
|
Observational | Recruiting | 2020-01 | China |
|
MSC-EVs in Acute/ Acute-on-Chronic Liver Failure After Liver Transplantation
NCT06825572 · ClinicalTrials.gov ↗ · Liver Failure, Mesenchymal Stem Cell, Extracellular Vesicles
|
Phase 1 | Not yet open | 2025-04 | China |
|
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
|
Phase 2 | Not yet open | 2024-09 | China |
|
The Clinical Cure Project of Chronic Hepatitis B in China
NCT04035837 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic
|
Phase 4 | Active, closed | 2018-05 | China |
|
PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure
NCT07409259 · ClinicalTrials.gov ↗ · Acute-on-Chronic Liver Failure (ACLF)
|
Phase EARLY_PHASE1 | Active, closed | 2026-01 | China |
|
Clinical Characteristics of Recompensation
NCT07651683 · ClinicalTrials.gov ↗ · Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus)
|
Observational | Active, closed | 2026-03 | China |
|
Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure
NCT06996392 · ClinicalTrials.gov ↗ · Acute-On-Chronic Liver Failure
|
Phase 1 | Active, closed | 2025-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 21 | 15 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Shenzhen Third People's Hospital | 1 |
Sponsors with the most current trials registered for this condition.
Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 21 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of its 21 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 7 drugs and biologicals as interventions. The most frequent are Atezolizumab (1), Bevacizumab (1), Entecavir (1), Methylprednisolone (1) and Ofatumumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.